Macrophages and pancreatic islet amyloidosis

Amyloid

Volumn 5, Issue 4, 1998, Pages 247-254

  De Koning, Eelco J P ^a,b,d   Van Den Brand, Joop J G ^a   Mott, Victoria L ^a   Chargé, Sophie B P ^a   Hansen, Barbara C ^c   Bodkin, Noni L ^c   Morris, John F ^b   Clark, Anne ^a,b  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

B cell; Diabetes; Fibril; Islet; Islet amyloid; Islet amyloid polypeptide; Lysosome; Macrophage; Phagocytosis

Indexed keywords

AMYLIN; AMYLOID;

AGED; AMYLOIDOSIS; ANIMAL; ARTICLE; COMPARATIVE STUDY; ELECTRON MICROSCOPY; GENETICS; HAPLORHINI; HUMAN; MACROPHAGE; METABOLISM; MIDDLE AGED; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; PATHOLOGY; RAT; TRANSGENIC MOUSE; ULTRASTRUCTURE;

AGED; AGED, 80 AND OVER; AMYLOID; AMYLOIDOSIS; ANIMALS; DIABETES MELLITUS, TYPE 2; HAPLORHINI; HUMANS; ISLETS OF LANGERHANS; MACROPHAGES; MICE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON; MIDDLE AGED; RATS;

EID: 0032243185     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506129809007297     Document Type: Article

References (33)

1. Westermark P and Grimelius L (1973). The pancreatic islet cell in insular amyloidosis in human diabetic and non-diabetic islets. Acta Path Microbiol Scand, section A, 81, 291-300
2. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJ, Holman RR, and Turner RC (1988). Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9(4): 151-9
3. Westermark P (1994). Amyloid and polypeptide hormones: what is their interrelationship? Amyloid: Int J Exp Clin Invest 1, 47-60
4. Maloy AL, Longnecker DS and Greenberg ER (1981). The relation of islet amyloid to the clinical type of diabetes. Human Pathol 12, 917-922
5. Hansen BC and Bodkin NL (1986). Heterogeneity of insulin responses: phases leading to type 2 (non-insulin dependent) diabetes mellitus in the rhesus monkey. Diabetologia 29, 713-719
6. de Koning EJP, Bodkin NL, Hansen BC and Clark A (1993). Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in β-cell population. Diabetologia 36, 378-384
7. O'Brien TD, Hayden DW, Johnson KH and Fletcher TF (1986). Immunohistochemical morphometry of pancreatic endocrine cells in diabetic normoglycemic glucose-intolerant and normal cats. J Comp Pathol 96, 357-369
8. Schneider HM, Störkel S and Will W (1980). Das Amyloid der Langerhansschen Inseln und seine Beziehung zum Diabetes Mellitus. Dtsch med Wschr 105, 1143-1147
9. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD and Johnson KH (1987). Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 84, 3881-3885
10. Clark A, Cooper GJ, Lewis CE, Morris JF, Willis AC, Reid KB and Turner RC (1987). Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet ii 231-234
11. Sanke T, Hanabusa T, Nakamo Y, Oki C, Okai K, Nishimura S, Kondo M and Nanjo K (1991). Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34, 129-132
12. Clark A, Morris JF, Scott LA, McLay A, Foulis AK, Bodkin NL and Hansen BC (1991). Intracellular formation of amyloid fibrils in ß-cells of human insulinoma and pre-diabetic monkey islets. In: Natvig JB, Førre O, Husby G, Husebekk A, Skogen B, Sletten K, Westermark P (eds) Amyloid and Amyloidosis. pp 453-456, Kluwer, Dordrecht, The Netherlands
13. Bari WA, Pettengill OS and Sorenson GD (1969). Electron microscopy and electron microscopic autoradiography of splenic cell cultures from mice with amyloidosis Lab Invest 20, 234-242
14. Castaño EM and Frangione B (1988). Biology of disease. Human amyloidosis, Alzheimer disease and related disorders. Lab Invest 58, 122-132
15. Zucker-Franklin D, Warfel A, Grusky G, Frangione B and Teitel D (1987). Novel monocyte-like properties of microglial/astroglial cells. Constitutive secretion of lysozyme and cystatin-C. Lab Invest 57, 176-185
16. Shirahama T, Cohen AS and Rodgers OG (1971). Phagocytosis of amyloid: in vitro interaction of mouse peritoneal macrophages with human amyloid fibrils and their accelerated uptake after dye binding. Exp Mol Path 14, 110-123
17. Westermark P (1973). Fine structure of the islets of Langerhans in insular amyloidosis. Virchows Arch Abt A Path Anat 359, 1-18
18. Mulder H, Lindh AC, Ekblad E, Westermark P and Sundler, F (1994). Islet amyloid polypeptide is expressed in endocrine cells of the gastric mucosa in the rat and mouse. Gastroenterology 107, 712-9
19. Verchere CB, D'Alessio DA, Palmiter RD, Weir GC, Bonner-Weir S, Baskin DG and Kahn SE (1996). Islet amyloid formation is associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93, 3492-6
20. Janson J, Soeller WC, Roche PC, Nelson RT, Torchia AJ, Kreutter DK and Butler PC (1996). Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 93, 7283-8
21. Couce M, Kane LA, O'Brien TD, Charlesworth J, Soeller W, McNeish J, Kreutter D, Roche P and Butler PC (1996). Treatment with growth hormone and dexamethazone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and beta cell dysfunction. Diabetes 45, 1094-1101
22. Fox N, Schrementi J, Nishi M, Ohagi S, Chan SJ, Heisserman JA, Westermark GT, Leckström A, Westermark P and Steiner DF (1993). Human islet amyloid polypeptide transgenic mice as a model of non-insulin dependent diabetes mellitus (NIDDM). FEBS Lett 323, 40-44
23. de Koning EJP, Höppener JWM, Verbeek JS, Oosterwijk C, van Hulst KL, Baker CA, Lips CJM, Morris JF and Clark A (1994). Human islet amyloid polypeptide accumulates at similar sites in islets of transgenic mice and humans. Diabetes 43, 640-644
24. de Koning EJP, Morris ER, Hofhuis FMA, Posthuma G, Höppener JWM, Morris JF, Capel PJA, Clark A and Verbeek JS (1994). Intra- and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 91, 8467-8471
25. Chargé SBP, de Koning EJP and Clark A (1995). Effect of pH and insulin on fibrillogenesis of islet amyloid polypeptide in vitro. Biochemistry 34, 14588-14593
26. Westermark P. Li ZC, Westermark GT, Leckström A and Steiner DF (1996). Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett 379, 203-6
27. Lorenzo A, Razzaboni B, Weir GC and Yankner BA (1994). Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368, 756-60
28. Rabinowitz SS, Horstmann H, Gordon S and Griffiths G (1992). Immunocytochemical characterization of the endocytic and phagolysosomal compartments in peritoneal macrophages. J Cell Biol 116, 95-112
29. Badman MK, Pryce RA, Chargé SBP, Morris JF and Clark A (1998). Fibrillar islet amyloid polypeptide is internalised by macrophages but resists proteolytic degradation Cell Tissue Res 291, 285-294
30. Clark A, Edwards CA, Ostle LR, Sutton R, Rothbard JB, Morris JF and Turner RC (1989). Localisation of islet amyloid peptide in lipofuscin bodies and secretory granules of human ß-cells and in islets of type 2 diabetic subjects. Cell Tissue Res 257, 179-85
31. Badman MK, de Koning EJP, Morris JF and Clark A (1995). Islet amyloid polypeptide accumulates in b-cell lysosomes of mouse islets exposed to leupeptin. Diabetic Med 12 Suppl 1 S6
32. Pepys MB, Baltz M, de Beer FC, Dyck RF, Holford S, Breathnach SM, Black MM, Tribe CR, Evans DJ and Feinstein A (1982). Biology of serum amyloid P component. Ann N Y Acad Sci 389, 286-297
33. Hawkins PN, Richardson S, MacSweeney JE, King AD, Vigushin DM, Lavender JP and Pepys MB (1993). Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. Q J Med 86, 365-374